UbiVac

Executive Summary

UbiVac is a private biopharmaceutical company developing DPV-001, a novel combination immunotherapy targeting the 'dark genome' to unlock cryptic epitopes for cancer treatment. At the SITC 2025 Annual Meeting, the company presented updated two-year overall survival data from its Phase 1/2 trial. Among PD-1-naïve patients, DPV-001 combination therapy achieved a median overall survival of 25.5 months, compared to 12.3 months for standard-of-care pembrolizumab, representing a compelling survival benefit. These results underscore the potential of UbiVac's approach to harness previously undruggable tumor antigens. The company is headquartered in Portland, Oregon, and continues to advance its pipeline with a focus on improving outcomes for patients with solid tumors.

Upcoming Catalysts (preview)

• Q4 2026Next Clinical Data Readout for DPV-00170% success
• TBDStrategic Partnership or Licensing Deal50% success
• Q2 2026Regulatory Guidance for Phase 2/3 Trial Design60% success